TriSalus Life Sciences Appoints Jodi Devlin as President of TriSalus Therapeutics
06 Septembre 2023 - 1:00PM
Business Wire
Devlin Brings Significant Expertise in
Commercialization, Sales and Marketing
TriSalus Life Sciences® Inc., (TriSalus or the Company), an
oncology company integrating its novel delivery technology with
immunotherapy to transform treatment for patients with liver and
pancreatic tumors, today announced that Jodi Devlin has joined the
Company as President of TriSalus Therapeutics.
In this newly established role, Ms. Devlin will be responsible
for developing and executing the go-to-market strategy for
TriSalus’ SD-101 therapeutic candidate, building the Company’s
therapeutic marketing operations, working with the clinical team to
incorporate commercial and payor needs into the clinical strategy,
developing and executing the Company’s patient access and payor
engagement strategy and developing a distinctive patient experience
for the SD-101 treatment.
“We are fortunate to have someone of Jodi’s caliber lead our
therapeutics team,” said Mary Szela, President and CEO of TriSalus.
“Jodi brings three decades of industry experience, developing
strategies and overseeing the successful commercialization and
launch of numerous drug candidates. We look forward to benefiting
from her leadership as she works with our clinical team to develop
a distinctive patient experience and execute a go-to-market
strategy for our SD-101 treatment.”
“I was drawn to TriSalus because of the Company’s unique,
integrated approach to treating liver and pancreatic tumors,
addressing immune dysfunction by combining immunotherapy drugs with
highly effective drug delivery technology to better help patients,”
said Ms. Devlin. “TriSalus’ disruptive technology and
immunotherapeutic platform is producing encouraging data in
clinical trials, and I’m pleased to be joining the Company at this
time. I look forward to working with Mary, Dr. Katz and the
clinical team to support the Company’s work to bring hope and
improved treatments to the lives of patients.”
About Jodi Devlin
Ms. Devlin bring over 34 years of experience in
biopharmaceuticals to TriSalus. Most recently, she served as Chief
Executive Officer of AltaThera Pharmaceuticals, a precision
medicine company using innovative science to improve patient care
and solve serious and costly problems, where she built the
Company’s vision and strategy, executed its turnaround, and oversaw
the FDA approval of its product. Prior to serving as CEO, she held
the role of Chief Commercial Officer at AltaThera, overseeing
sales, marketing, pricing, reimbursement, and health economics.
Prior to that, Ms. Devlin served as the Vice President and General
Manager of the Hospital Acute Care business at Mallinckrodt
Pharmaceuticals, a global specialty pharmaceutical company, where
she led the strategy and commercialization of Ofirmev, a non-opioid
pain drug, and surgical hemostats. Ms. Devlin has also served as a
Senior Executive at Baxter/Baxalta, a global, diversified
healthcare company developing, manufacturing and marketing products
that save and sustain the lives of people with hemophilia, immune
disorders, cancer, infectious diseases, kidney disease, trauma and
other chronic and acute medical conditions, and Abbott AbbVie, a
pharmaceutical company that discovers and delivers innovative
medicines, where she led the commercialization, launch and clinical
strategy for over 20 products, including the Company’s flagship
product HUMIRA. She currently serves on the Board of Directors of
Fitabeo Therapeutics, a specialty pharmaceutical company that
advances and commercializes medicines to solve critical healthcare
problems.
Ms. Devlin holds a Bachelor of Science in Nursing degree from
Oklahoma University and a Master of Business Administration from
Washington University’s Olin School of Business.
About TriSalus Life Sciences
TriSalus Life Sciences® is an oncology company integrating novel
delivery technology with immunotherapy to transform treatment for
patients with liver and pancreatic tumors.
The Company’s platform includes devices that utilize a
proprietary drug delivery technology and a clinical stage
investigational immunotherapy. The Company’s two FDA-cleared
devices use its proprietary Pressure-Enabled Drug Delivery™ (PEDD)
approach to deliver a range of therapeutics: the TriNav® Infusion
System for hepatic arterial infusion of liver tumors and the
Pancreatic Retrograde Venous Infusion System for pancreatic tumors.
PEDD is a novel delivery approach designed to address the anatomic
limitations of arterial infusion for the pancreas. The PEDD
approach modulates pressure and flow in a manner that delivers more
therapeutic to the tumor and is designed to reduce undesired
delivery to normal tissue, bringing the potential to improve
patient outcomes. SD-101, the Company’s investigational
immunotherapeutic candidate, is designed to improve patient
outcomes by treating the immunosuppressive environment created by
many tumors and which can make current immunotherapies ineffective
in the liver and pancreas. Patient data generated during
Pressure-Enabled Regional Immuno-Oncology™ (PERIO) clinical trials
support the hypothesis that SD-101 delivered via PEDD may have
favorable immune effects within the liver and systemically.
In partnership with leading cancer centers across the country –
and by leveraging deep immuno-oncology expertise and inventive
technology development – TriSalus is committed to advancing
innovation that improves outcomes for patients. Learn more at
trisaluslifesci.com and follow us on Twitter @TriSalusLifeSci and
LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230905090653/en/
Media: press@trisaluslifesci.com
TriSalus Life Sciences (NASDAQ:TLSI)
Graphique Historique de l'Action
De Août 2024 à Sept 2024
TriSalus Life Sciences (NASDAQ:TLSI)
Graphique Historique de l'Action
De Sept 2023 à Sept 2024